Fluoroquinolone-Associated Disability

FQAD is the prototype subtype of DIMD — regulatorily documented, molecularly confirmed, and the most extensively studied example of drug-induced mitochondrial injury producing delayed, persistent, multisystem disability.

FDA Docket FDA-2026-P-5116 — Citizen Petition Accepted

Reinhardt et al. 2025 — AIFM1 & IDH2 confirmed off-targets

Definition

Not a Controversy — A Reality

FQAD — Fluoroquinolone-Associated Disability

A syndrome of delayed, persistent, and potentially disabling adverse effects involving tendons, muscles, joints, peripheral nerves, and the central nervous system following exposure to fluoroquinolone antibiotics.

FQAD is not a patient-invented diagnosis. It is a recognized clinical syndrome — formally acknowledged by the U.S. Food and Drug Administration and the European Medicines Agency following years of accumulating safety signals and patient reports that could no longer be dismissed.

What distinguishes FQAD from other drug adverse effects is its multisystem nature, delayed onset, and persistence long after the antibiotic has cleared the body. Patients describe symptoms emerging days to weeks after completing a course — and in some cases, continuing to worsen for months or years.

"The drug is gone. The damage is not. That is not a coincidence — it is a mechanism."

Fluoroquinolones are among the most widely prescribed antibiotic classes in the world. Ciprofloxacin, levofloxacin, and moxifloxacin are routinely used for urinary tract infections, respiratory infections, and a broad range of indications — often in patients who were previously healthy and had no warning that a standard course of antibiotics could produce lasting disability.

Regulatory Record

Key Regulatory Milestones

2008

FDA Boxed Warning — Tendinopathy & Rupture

FDA adds black box warning to all systemic fluoroquinolones for risk of tendinitis and tendon rupture, including risk persisting after discontinuation.

2013

FDA Warning — Peripheral Neuropathy

FDA updates labeling to warn that peripheral neuropathy may occur "soon after" initiation and may be permanent — a landmark acknowledgment of irreversibility.

2016

FDA Safety Communication — Disabling & Potentially Permanent Effects

FDA issues Drug Safety Communication explicitly describing "disabling and potentially permanent serious side effects" involving tendons, muscles, joints, nerves, and the CNS. Recommends restricting use for minor infections. First use of the word permanent in this context.

2018

EMA Restriction — Disabling Musculoskeletal & Nervous System Effects

European Medicines Agency recommends restrictions on fluoroquinolone use, citing disabling and long-lasting adverse reactions affecting the musculoskeletal system and nervous system.

2026

FDA Citizen Petition — Enhanced Informed Consent

Docket FDA-2026-P-5116 accepted for filing. Requests stronger informed-consent language and improved patient-facing risk communication to reflect what the regulatory record already documents.

Historical Arc

Two Parallel Stories — One Widening Gap

Mitochondrial science advanced dramatically from the 1960s onward — confirming mechanisms, mapping pathways, and accumulating evidence of drug-induced energy system injury. Fluoroquinolone safety frameworks moved far more slowly. The gap between what biology knew and what regulation reflected is the structural problem this initiative exists to close. Click any science milestone to expand the mechanistic detail.

Fluoroquinolone regulatory & clinical record

Mitochondrial science advancing

Nalidixic acid — first quinolone

Discovered 1962 as a byproduct of chloroquine synthesis. Narrow-spectrum, oral, urinary tract use only. The molecular ancestor of all fluoroquinolones.

Origin

1962

Mitchell's chemiosmotic hypothesis

Peter Mitchell proposes that ATP is generated by a proton gradient across the inner mitochondrial membrane — not by direct chemistry as previously believed.

Foundational theory

Why it matters for DIMD: Chemiosmosis established that mitochondrial energy production depends entirely on membrane integrity and the electrochemical gradient. Any drug that disrupts membrane potential — as fluoroquinolones do — attacks the very mechanism Mitchell described. This hypothesis, confirmed by Nobel Prize in 1978, is the theoretical foundation for understanding why mitochondrial membrane disruption produces systemic energy failure.

Key reference: Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature. 1961;191:144–148.

Ciprofloxacin approved — FDA

1987. Second-generation fluoroquinolone with broad-spectrum activity and rapid adoption across medicine. Levofloxacin, moxifloxacin follow. The class enters widespread clinical use globally.

Class expansion

1980s

First complete human mtDNA sequenced

Anderson et al. (1981) publish the complete 16,569-base-pair sequence of human mitochondrial DNA — encoding 13 proteins, 22 tRNAs, and 2 rRNAs.

Structural milestone

Why it matters for DIMD: Sequencing human mtDNA revealed its unique vulnerability — no protective histones, limited repair mechanisms, proximity to the electron transport chain. These features make mtDNA far more susceptible to drug-induced damage than nuclear DNA. Ciprofloxacin was being approved for clinical use at exactly the same time science was mapping the vulnerability of the genome it would damage.

Key reference: Anderson S, et al. Sequence and organization of the human mitochondrial genome. Nature. 1981;290:457–465.

Early adverse event reports emerge

Sporadic reports of tendinopathy, CNS effects, and peripheral neuropathy begin appearing in the literature and FDA MedWatch. No labeling action taken.

Signal emerging

1988

mtDNA mutations linked to human disease

Wallace et al. demonstrate that point mutations in mitochondrial DNA cause inherited human diseases — establishing that mtDNA integrity is directly linked to clinical phenotype.

★ Landmark

Why it matters for DIMD: Wallace's 1988 papers established that mtDNA mutations produce multisystem disease affecting tissues with the highest energy demands — exactly the pattern seen in FQAD. They also demonstrated heteroplasmy: a mixture of wild-type and mutant mtDNA exists within cells, and clinical disease emerges when the mutant fraction crosses a threshold. This is precisely the propagation mechanism in the DIMD five-step framework — fluoroquinolone-induced damage shifts heteroplasmy toward dysfunction through a self-sustaining replication bias.

Key reference: Wallace DC, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science. 1988;242:1427–1430.

Tendon rupture case series published

Growing literature on Achilles tendon rupture following FQ use. FDA receives spontaneous reports but does not yet act on labeling. The class continues expanding.

Signal accumulating

1996

Ciprofloxacin cleaves mitochondrial DNA

Lawrence et al. demonstrate that ciprofloxacin causes delayed cytotoxicity and directly cleaves mitochondrial DNA in mammalian cells — independent of its antibacterial mechanism.

★ Direct evidence

Why it matters for DIMD: This 1996 study is among the earliest direct experimental evidence that ciprofloxacin damages mammalian mitochondrial DNA through inhibition of mitochondrial topoisomerase II (TOP2β). The "delayed cytotoxicity" finding is particularly significant: cells did not die immediately — damage accumulated over time, producing a delayed phenotype. This is the experimental model for the pharmacokinetic-clinical mismatch at the center of FQAD: the drug clears rapidly, but the mtDNA damage and its downstream consequences persist and evolve.

Key reference: Lawrence JW, Claire DC, Weissig V, Rowe TC. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Mol Pharmacol. 1996;50(5):1178–1188.

Trovafloxacin withdrawn — hepatotoxicity

Trovafloxacin (Trovan) withdrawn from general use due to severe hepatotoxicity and liver failure. An early signal that this drug class carries serious organ-level mitochondrial toxicity beyond its antimicrobial profile.

Class safety event

Early 2000s

PINK1/Parkin mitophagy pathway characterized

The molecular pathway by which cells selectively clear damaged mitochondria is characterized — establishing a quality control system specifically designed to remove dysfunctional mitochondria.

Quality control

Why it matters for DIMD: The PINK1/Parkin pathway is mitochondrial quality control (MQC) — the cellular system that identifies and clears damaged mitochondria. In the DIMD five-step framework, Step 3 describes what happens when this system is overwhelmed by drug-induced injury: incomplete clearance allows damaged mitochondria to persist and propagate. Understanding PINK1/Parkin is essential for understanding why FQAD doesn't resolve when the drug clears — the quality control system that should fix the problem has been saturated and cannot keep pace with the rate of damage.

FDA black box warning — tendinitis & tendon rupture

FDA mandates a boxed warning for all systemic fluoroquinolones. Tendon rupture risk may persist months after discontinuation — the first regulatory acknowledgment that effects outlast drug presence.

Boxed warning added

2008

Mitochondria-ER contact sites (MAMs) mapped

Mitochondria-associated membranes (MAMs) — physical contact sites between mitochondria and the endoplasmic reticulum — are characterized as critical hubs for calcium transfer, lipid metabolism, and apoptosis signaling.

Signaling architecture

Why it matters for DIMD: MAMs explain how mitochondrial dysfunction propagates beyond the organelle itself. When FQ-induced injury disrupts mitochondrial calcium homeostasis, dysregulation spreads via MAMs to the ER — affecting protein folding, stress responses, and apoptotic signaling across the entire cell. This is part of why FQAD is multisystem: it's not just energy failure, it's a cascade of cellular communication disruption that starts at the mitochondria and radiates outward. MAM dysregulation is now implicated in neurodegeneration, metabolic disease, and inflammation — all phenotypes seen in FQAD.

FDA — peripheral neuropathy may be permanent

FDA updates labeling acknowledging that FQ-associated peripheral neuropathy may be permanent — regulatory acknowledgment of irreversibility for a nervous system adverse effect of a routinely prescribed antibiotic.

Permanence acknowledged

2013

Bactericidal antibiotics induce mitochondrial ROS in mammalian cells

Kalghatgi et al. demonstrate that bactericidal antibiotics — including fluoroquinolones — induce mitochondrial dysfunction and oxidative damage in mammalian cells through ROS generation, independent of their antibacterial mechanism.

★ Key study

Why it matters for DIMD: The Kalghatgi 2013 paper in Science Translational Medicine demonstrated in human cells — at clinically relevant concentrations — that fluoroquinolones generate mitochondrial ROS, deplete glutathione, impair membrane potential, and reduce oxidative phosphorylation. Published the same year FDA acknowledged permanent neuropathy without naming the mechanism causing it. The science and the regulatory action were running in parallel, unconnected.

Key reference: Kalghatgi S, et al. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in mammalian cells. Sci Transl Med. 2013;5(192):192ra85.

FDA — "disabling and potentially permanent" multisystem effects

FDA Drug Safety Communication explicitly names disabling and potentially permanent effects across tendons, muscles, joints, nerves, and CNS simultaneously — the closest regulatory acknowledgment of the multisystem FQAD syndrome.

Landmark communication

2016

Mitochondrial fission/fusion dynamics fully characterized

The molecular machinery governing mitochondrial fission (DRP1, FIS1) and fusion (MFN1/2, OPA1) is characterized — establishing that mitochondria are dynamic networks, not static organelles. Nobel Prize for related autophagy mechanisms awarded 2016.

Network dynamics

Why it matters for DIMD: Fission/fusion is part of the quality control system that segregates damaged from healthy mitochondria. FQ-induced injury overwhelms this system — the rate of damage exceeds the capacity of fission/fusion dynamics to isolate and clear damaged organelles. Damaged mitochondria persist, fuse with healthy ones, and spread dysfunction across the mitochondrial population. This is the cellular mechanism underlying Step 4 of the DIMD framework — the propagation that continues after the drug has cleared.

EMA restricts fluoroquinolone use — EU

European Medicines Agency cites disabling and long-lasting musculoskeletal and nervous system adverse reactions. International confirmation that this is not a US-specific safety signal.

International action

2018

Ciprofloxacin impairs mtDNA replication via TOP2β inhibition

Hangas et al. demonstrate that ciprofloxacin specifically impairs mitochondrial DNA replication initiation through inhibition of topoisomerase 2 — mechanistically confirming the TOP2β pathway in human cells.

★ Mechanism confirmed

Why it matters for DIMD: Hangas 2018 provided the mechanistic precision that Lawrence 1996 had first indicated: ciprofloxacin doesn't just damage mtDNA nonspecifically — it impairs mtDNA replication initiation by inhibiting the specific topoisomerase required to manage DNA topology during replication. The consequence is that damaged replication forks accumulate, mtDNA copy number drops, and the cell cannot replace the mitochondrial proteins encoded by that DNA. Confirmed the same year EMA imposed prescribing restrictions based on clinical consequences of this exact mechanism.

Key reference: Hangas A, et al. Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of topoisomerase 2. Nucleic Acids Res. 2018;46(18):9625–9636.

No updated safety framework

Despite accumulating molecular evidence and regulatory actions across three decades, no systemic update to prescribing frameworks, mitochondrial safety endpoints, or longitudinal tracking systems exists.

Gap persists

2025

AIFM1 & IDH2 confirmed as direct FQ off-targets

Reinhardt et al. use thermal proteome profiling to identify AIFM1 and IDH2 as validated direct binding targets of fluoroquinolones in human cells — confirming downstream downregulation of Complexes I and IV.

★ Validated · 2025

Why it matters for DIMD: Reinhardt 2025 is the molecular foundation the DIMD framework rests on. AIFM1 is required for assembly and function of respiratory Complexes I and IV. IDH2 generates NADPH — the primary currency of the mitochondrial antioxidant system. With AIFM1 bound and inhibited, Complex I and IV biogenesis is impaired. With IDH2 inhibited, the cell cannot regenerate antioxidants needed to counter the resulting ROS surge. These are empirically confirmed human-cell interactions — published nearly 30 years after Lawrence first showed that cipro cleaves mammalian mtDNA, and the same year no new regulatory framework appeared in response.

Key reference: Reinhardt T, et al. Chemical proteomics reveals human off-targets of fluoroquinolone-induced mitochondrial toxicity. Angew Chem Int Ed. 2025;64(18):e202421124.

FDA Petition FDA-2026-P-5116 accepted

Citizen Petition requesting enhanced informed consent for systemic fluoroquinolones accepted for filing. Open for public comment. The regulatory record and the molecular science are finally being brought into alignment.

Petition filed · Now

2026

Mitochondrial vulnerability confirmed independently — cardiac

Mori et al. (Nature Communications, 2026) demonstrate that subclinical mitochondrial vulnerability — clinically silent at baseline — can be unmasked by biological stress, triggering cardiac dysfunction through mitochondrial ROS and necroptosis.

★ Independent validation

Why it matters for DIMD: Mori 2026 comes from a completely independent research group studying a completely different exposure and arrives at the same conclusion: pre-existing mitochondrial vulnerability is a real, measurable risk factor that standard safety evaluation does not account for. Subclinical dysfunction, compensated at baseline, was unmasked under stress and produced organ damage. This is the second-hit phenomenon in a different context — and when two independent groups using different methods studying different exposures converge on the same mechanism, the scientific argument becomes substantially stronger.

Key reference: Mori G, et al. Mitochondrial vulnerability underlies myocarditis from COVID-19 mRNA vaccine. Nature Communications. 2026. DOI: 10.1038/s41467-026-71295-1.

The gap this initiative exists to close: Mitochondrial science confirmed the mechanism decades before safety frameworks reflected it. From Lawrence 1996 to Reinhardt 2025, the evidence accumulated. The regulatory response lagged at every step. That ends now — with a petition on file, a manuscript under review, and a registry building the evidence base.

Confirmed Molecular Targets

What Fluoroquinolones Actually Do Inside Cells

For decades, fluoroquinolone toxicity was attributed primarily to topoisomerase inhibition — a well-understood mechanism responsible for the antibacterial effect. But this explanation was always incomplete. It did not account for the multisystem, mitochondrial, and delayed nature of the adverse effects seen clinically.

The 2025 chemical proteomics study by Reinhardt and colleagues changed this. Using thermal proteome profiling in human cells, the study identified previously unknown direct binding targets — and the findings directly validate key elements of the DIMD mechanistic framework.

Chemical Proteomics · Angewandte Chemie · 2025

Chemical proteomics reveals human off-targets of fluoroquinolone-induced mitochondrial toxicity

Reinhardt T, El Harraoui Y, Rothemann A, et al. · Angew Chem Int Ed. 2025;64(18):e202421124

Using thermal proteome profiling in human cells, this study identified AIFM1 (Apoptosis-Inducing Factor Mitochondria-Associated 1) and IDH2 (Isocitrate Dehydrogenase 2) as validated direct off-targets of fluoroquinolone binding — and confirmed downstream downregulation of mitochondrial Complexes I and IV. These are not predicted or theoretical interactions. They are empirically confirmed in human cell systems.

This study is the molecular foundation beneath what patients and regulators have been observing for thirty years. The mechanism is no longer theoretical.

The Multi-Hit Insult

Four Simultaneous Strikes on the Energy System

TOP2β Inhibition — mtDNA Topology Disruption

Fluoroquinolones inhibit bacterial topoisomerase II — but also human mitochondrial topoisomerase IIβ (TOP2β), disrupting mtDNA topology, replication fidelity, and structural integrity of the mitochondrial genome.

AIFM1 Binding — Complex I & IV Impairment

Direct binding to AIFM1 (Apoptosis-Inducing Factor Mitochondria-Associated 1) impairs the biogenesis and assembly of respiratory chain Complexes I and IV — the primary engines of mitochondrial energy production.

Confirmed · Reinhardt 2025

IDH2 Inhibition — Antioxidant Capacity Depleted

Direct inhibition of IDH2 (Isocitrate Dehydrogenase 2) reduces mitochondrial NADPH production — the key currency of the mitochondrial antioxidant system. This leaves mitochondria unable to quench the ROS surge that follows the other hits.

Confirmed · Reinhardt 2025

ROS Surge & mtDNA Copy Number Depletion

The combination of impaired electron transport, depleted antioxidant capacity, and mtDNA structural damage triggers a reactive oxygen species surge — and rapid depletion of mitochondrial DNA copy number, removing the cell's ability to replace damaged mitochondrial components.

Clinical Pattern

The Multisystem Phenotype — and Why It Gets Misattributed

Because FQAD crosses organ systems and follows a delayed onset pattern, it is routinely fragmented into separate specialty diagnoses. Each specialist sees their piece of the picture — the neurologist sees neuropathy, the rheumatologist sees connective tissue dysfunction, the cardiologist sees dysautonomia — without a framework that unifies them. The following table maps common diagnostic categories to their underlying mitochondrial mechanisms within the DIMD framework.

Common Misattributed Category	Typical Presentation in FQAD	Underlying Mitochondrial Mechanism
Fibromyalgia-like syndrome	Widespread musculoskeletal pain, fatigue, tender points, sleep disruption	Bioenergetic dysfunction, oxidative stress, mitochondrial quality control impairment
ME/CFS-like syndrome	Post-exertional malaise, profound fatigue disproportionate to activity, cognitive dysfunction	Impaired ATP reserve, ROS amplification, failure of bioenergetic threshold under exertion
Peripheral neuropathy	Burning, tingling, numbness in extremities; electric shock sensations; sensory loss	Neuronal mitochondrial vulnerability; high energy demand of peripheral axons; Complex I/IV impairment
Dysautonomia / POTS-like syndrome	Heart rate instability, orthostatic intolerance, blood pressure dysregulation, temperature dysregulation	Autonomic nervous system bioenergetic failure; impaired mitochondrial function in autonomic neurons
Cognitive dysfunction syndrome	Brain fog, memory impairment, word-finding difficulty, impaired processing speed	Neuronal calcium dysregulation, ROS-mediated synaptic dysfunction, CNS bioenergetic deficit
Connective tissue / musculoskeletal disorder	Tendon pain and rupture, joint hypermobility, muscle weakness, recurrent injury	Oxidative damage to collagen-producing cells; impaired tissue repair via mitochondrial ROS; TOP2β-mediated mtDNA damage in tenocytes
Anxiety / psychiatric disorder	New-onset anxiety, panic attacks, depersonalization, emotional dysregulation	Neuronal mitochondrial dysfunction; altered neurotransmitter synthesis dependent on mitochondrial cofactors; hippocampal bioenergetic stress
Idiopathic multisystem illness	Symptoms spanning multiple systems with no unifying diagnosis; labeled functional or psychosomatic	Systemic bioenergetic failure — the unified mechanism that organ-based frameworks cannot see as a single entity

Source: Clinical overlap framework from the DIMD systems-level preprint (DOI: 10.5281/zenodo.20015205). Each overlap reflects a distinct mitochondrial mechanism, not coincidental symptom similarity.

The Second-Hit Phenomenon

When a Primed System Meets Another Exposure

One of the most clinically important — and least recognized — aspects of FQAD is what happens when a patient with prior fluoroquinolone exposure receives a second course. Or a different mitochondria-impairing medication. Or undergoes significant physiological stress.

In a mitochondrially primed system — one where MQC capacity has already been depleted, heteroplasmy has already shifted, and bioenergetic reserve is already reduced — a subsequent insult does not produce a proportional response. It can produce a disproportionate, catastrophic escalation.

This is the "second-hit" phenomenon. Patients who tolerated a first fluoroquinolone course with manageable effects sometimes describe the second course as the one that changed everything — a sudden, dramatic worsening from which they did not recover.

This pattern is not coincidence, and it is not psychological sensitization. It is an expected outcome of mitochondrial population dynamics in a system that has already crossed a critical threshold.

Currently, no prescribing system flags prior fluoroquinolone adverse effects when a new prescription is written. No electronic health record alerts a clinician that this patient has a history suggestive of FQAD before a second course is initiated. This is the gap the DIMD framework and the FDA petition exist to address.

First Exposure

Standard Course of Fluoroquinolone

Drug clears within days. Patient may notice fatigue, joint discomfort, or neurologic symptoms — often dismissed or attributed to the original infection. MQC systems are stressed but partially compensate. Bioenergetic reserve is reduced. Heteroplasmy begins to shift.

The Primed State

Mitochondrially Vulnerable System

Months or years pass. Patient may be "functional" but operating with reduced bioenergetic reserve. Subclinical mitochondrial dysfunction is present but compensated — clinically silent, not detectable by standard workup. The system is primed.

Second Hit

Disproportionate Escalation

A second fluoroquinolone course — or another mitochondria-impairing drug, or significant physiological stress — strikes a system with depleted reserve and no buffer. The result is a catastrophic escalation that can produce permanent, severe, multisystem disability. The second hit is not the cause. The primed system is.

Clinical Recognition

ICD-10-CM Coding for Fluoroquinolone Adverse Effects

ICD-10-CM fluoroquinolone adverse effect codes exist in the 2025 coding system — providing a mechanism for clinicians to document and track fluoroquinolone-related adverse effects in the medical record. Their clinical utility depends entirely on clinician awareness that these codes exist and should be applied.

Proper coding creates the longitudinal data trail that pharmacovigilance needs. An adverse effect that is never coded is an adverse effect that never exists in the data — and cannot be counted, tracked, or used to inform future safety decisions.

When a patient presents with symptoms consistent with FQAD — neuropathy, tendinopathy, fatigue, cognitive dysfunction, dysautonomia — and there is a history of fluoroquinolone exposure, documenting that exposure in the medical record is not speculation. It is accurate clinical documentation.

For clinicians: Proper use of fluoroquinolone adverse effect codes supports both individual patient care and population-level pharmacovigilance. Coding the exposure-effect relationship is a clinical and public health responsibility — not an assignment of legal blame.

J02.0X5A

Adverse Effect of Fluoroquinolones — Initial Encounter

Use for the initial encounter when documenting an adverse effect of a fluoroquinolone antibiotic that was properly prescribed and administered.

J02.0X5D

Adverse Effect of Fluoroquinolones — Subsequent Encounter

Use for ongoing follow-up encounters for the same adverse effect event.

J02.0X5S

Adverse Effect of Fluoroquinolones — Sequela

Use for late effects and sequelae — the persistent or delayed consequences that continue after the initial adverse effect period. This is the code most applicable to FQAD presentations.

M79.2

Neuralgia & Neuritis, Unspecified

May be used in conjunction with the adverse effect code to document neuropathic pain components. Code the adverse effect first.

M76.6–

Achilles Tendinitis / Tendon Rupture

Tendon-specific codes should be used alongside the adverse effect code when tendinopathy is a presenting component. Document the drug exposure as the underlying cause.

FDA Citizen Petition · Docket FDA-2026-P-5116

Requesting Enhanced Informed Consent for Systemic Fluoroquinolone Antibiotics

Accepted for filing · Open for public comment on regulations.gov · DOI: 10.5281/zenodo.20128765

Read the Petition

The Evidence Exists. The Framework Exists. Now We Build the Record.

Every patient who submits a registry record, every clinician who codes correctly, every policymaker who reads the petition — that is how the evidence base grows.

Join the Registry Take Action